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Cells of the human immune system have been shown to ex-
press somatostatin receptors (sst). The expression of sst sug-
gests a functional role of the peptide somatostatin (SS). How-
ever, SS expression has not been demonstrated yet in different
human immune tissues. Therefore, we investigated by RT-
PCR the expression of both SS and cortistatin (CST), a SS-like
peptide, in various human lymphoid tissues and immune cells.
We detected SS mRNA expression in the human thymus only,
while not in thymocytes. CST mRNA was clearly expressed in
the immune cells, lymphoid tissues, and bone marrow. Using
quantitative RT-PCR, significant differences in expression
levels between tissues were demonstrated. Expression of CST
mRNA was up-regulated during differentiation of monocytes
into macrophages and dendritic cells and could be up-regu-
lated by lipopolysaccharide stimulation. Two differently sized
cDNA fragments of CST were detected in the majority of cells
and tissues. However, although both fragments were detected
in nearly all T-cell lines (7 of 8), most of the B-cell lines ex-
pressed the short fragment only (8 of 10). Using autoradiog-
raphy, we showed that CST displaced [125I-Tyr3]octreotide
binding with relatively high affinity on human thymic tissue
and sst2-expressing cells. This is the first extensive study dem-
onstrating that human lymphoid tissues and immune cells
express different levels of CST mRNA and that its expression
can be regulated. On the basis of these observations, we hy-
pothesize a role for CST as an endogenous ligand of at least the
sst2 receptor in the human immune system, rather than SS
itself. (J Clin Endocrinol Metab 88: 270–276, 2003)
SOMATOSTATIN (SS) IS a neuropeptide that is widelydistributed throughout the human body. The central
nervous system, gastrointestinal tract, and endocrine glands
are the major sites of production (1, 2). SS has a predomi-
nantly inhibitory action, especially with regard to the release
of mediators, such as hormones (3, 4). The action of SS is
mediated through G protein-coupled seven transmembrane
receptors of which five different receptors were cloned,
named sst1–5 (5). The receptor subtypes show a specific dis-
tribution in different organs, and the natural ligands SS-14
and SS-28 both have high binding affinity to all five receptor
subtypes (5). The sst family can be divided into two sub-
classes, the first consisting of sst2, sst3, and sst5 and the
second consisting of sst1 and sst4, on the basis of differential
binding affinities of the various ligands (6). Conformation-
ally restricted octapeptide analogs of SS bind with low af-
finity to sst1 and sst4, whereas these analogs bind with higher
affinity to sst2, sst3, and sst5 receptors. Recently, a peptide
bearing strong structural resemblance to SS was discovered.
This peptide, named cortistatin (CST), has an identical re-
ceptor binding domain (7) and binds with high affinity to all
five human sst subtypes (8). CST mRNA was first found to
be expressed in the human brain, but in further studies it was
also found in other tissues such as stomach, kidney, and
leukocytes (9). Until now, no specific receptor for CST has
been found. Expression studies by RT-PCR showed that with
different primer sets, two differently sized cDNA fragments
could be detected, a 317-bp fragment in the human brain,
kidney, stomach, and leukocytes, and a 701-bp fragment
selectively expressed in the human brain (9).
In previous studies, a differential expression of sst in hu-
man immune cells and tissues has been observed. This dif-
ferential expression of sst on immune cells suggests that
these receptors play a role in the human immune system (10).
Little is known, however, with respect to the expression of
SS in the human immune system. In the human thymus, SS
mRNA was found to be synthesized in the epithelial and not
in the lymphoid component (11). To explore the expression
of SS and its related compound CST, we investigated mRNA
expression of SS and CST (isoforms) by RT-PCR in different
immune tissues, such as thymus, spleen, and bone marrow.
In the human thymus, we distinguished thymic epithelial
cells (TEC) from thymocytes to investigate whether differ-
ences in expression of CST and SS mRNA exist between these
cells in this organ. Moreover, a number of human immune
cell subsets, i.e. peripheral blood leukocytes (PBMC), mono-
cytes, macrophages, dendritic cells, and B- and T-lympho-
cytes were studied as well. Finally, SS and CST mRNA ex-
pression was evaluated in human T- and B-cell lines of
different maturation levels. Using quantitative RT-PCR (Q-
PCR), differences in expression levels of CST mRNA between
immune cells and tissues were investigated. Monocytes and
monocyte-derived macrophages, both unstimulated and li-
popolysaccharide (LPS)-stimulated, were evaluated to get
insight into the regulation of CST mRNA expression during
Abbreviations: CST, Cortistatin; HPRT, hypoxanthine-guanine phos-
phoribosyl transferase; LPS, lipopolysaccharide; PBMC, peripheral
blood mononuclear cells; Q-PCR, quantitative RT-PCR; SS, somatostatin;
sst, somatostatin receptor(s); TEC, thymic epithelial cells.
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differentiation of monocytes as well as in cells in activated
state. In addition to the mRNA studies, we performed re-
ceptor autoradiographic studies using [125I-Tyr3]octreotide
on human thymic tissue and sst2-transfected cells to evaluate
whether CST is able to bind to sst receptors in human im-
mune tissue.
Materials and Methods
Isolation of blood mononuclear cells
PBMC were isolated from buffy coats by Ficoll (Pharmacia & Upjohn
Diagnostics AB, Uppsala, Sweden; density, 1.077 g/ml) density gradient
centrifugation. Subsequently, B- and T-lymphocytes were separated
from PBMC using CD19 and CD3 antibody-coated magnetic beads,
respectively, as described previously in detail (11). Monocytes were
isolated from the PBMC fraction using a Percoll (Pharmacia & Upjohn
Diagnostics AB; density, 1.063 g/ml) density gradient centrifugation as
described before (12). Isolated cells were frozen in 10% dimethylsulf-
oxide medium and stored in 80 C until use.
Cell culture
Monocytes were cultured and allowed to differentiate into macro-
phages and dendritic cells as described before (13). Fluorescence-acti-
vated cell sorting analysis (data not shown) confirmed phenotypes of the
cultured cells. Monocytes and macrophages were stimulated for 24 h
with LPS (Sigma Aldrich bv, Zwijndrecht, The Netherlands) at a final
concentration of 2 g/ml. Thereafter, cells were collected and stored at
80 C.
T- and B-cell lines
The human cell lines that we used included CD3 (HSB-2, Molt-3,
ALL-1, MT-1), TCR (Peer), or TCR (Molt-16, HuT-78, HPB-ALL)
T-cell lines; and precursor (RS4,11, Nalm-1, BV-173, Nalm-6), mature
Burkitt (Raji, Daudi, JY, TMM), and plasma (LP-1, L-363) B-cell lines.
Total RNA preparations from these cells were isolated as described
before (14).
Samples
Normal thymic tissues were obtained from children during cardio-
vascular surgery. Thymic epithelial cells were collected as described in
detail previously (11). Thymocytes were collected using a filter chamber
(NPBI, Emmer-Compascuum, The Netherlands). Splenic tissue was ob-
tained from patients suffering from splenic rupture. The protocols were
in accordance with the Helsinki Doctrine on Human Experimentation.
Informed consent was obtained. Samples were taken directly at oper-
ation, quickly frozen on dry ice, and stored at 80 C. Tissue was
squeezed and lysed before use as described below. Human bone marrow
cells were obtained from healthy donors after informed consent.
RT-PCR studies
RT-PCR was performed as described previously (11). Briefly, poly A
mRNA from tissue samples and cells was isolated using Dynabeads
Oligo (dT)25 (DynAl AS, Oslo, Norway). cDNA was synthesized from
the poly A mRNA, which was eluted from the beads in H2O for 10 min
at 65 C, using Oligo (dT)12–18 Primer (Life Technologies, Inc., Gaithers-
burg, MD). Twenty microliters of the cDNA was used for each PCR
amplification using primer sets for human SS, CST, and hypoxanthine-
guanine phosphoribosyl transferase [(HPRT) as a control; Table 1]. Two
different primer sets were used, CST A and B, to detect expected cDNA
fragments of 173 bp and 701 bp, respectively (Fig. 1 and Ref. 9). cDNA
of human brain RNA (Invitrogen, Groningen, The Netherlands) was
used as a positive control. The PCR was performed as described before
(11). Identities of the products were confirmed by direct sequencing
using an ABI Prism 3100 Genetic Analyzer (PE Applied Biosystems,
Utrecht, The Netherlands) according to the manufacturer’s protocol.
Q-PCR studies
Total RNA was isolated using either a High Pure RNA Tissue Kit or
High Pure RNA Isolation Kit (Roche Diagnostics GmbH, Mannheim,
Germany) for tissue and cell samples, respectively, according to the
manufacturer’s protocol. cDNA was synthesized in a reverse transcrip-
tion reaction as described previously (11), using 2000 ng total RNA per
reaction in a total volume of 40 l. Q-PCR was performed using TaqMan
Universal PCR Master Mix (PE Applied Biosystems), 300 nm forward
primer, 300 nm reverse primer, 200 nm probe, and 1 l cDNA template,
corresponding to 50 ng total RNA in the reverse transcription reaction,
in a total reaction volume of 25 l. The reactions were performed in an
ABI 7700 Sequence Detector (Perkin-Elmer Corp., Oosterhout, The Neth-
erlands). After an initial heating at 95 C for 8 min, samples were sub-
jected to 40 cycles of denaturation at 95 C for 15 sec and annealing for
1 min at 60 C. The primer sequences we used included: CST forward,
5-GGAGAGAAGCTCCAGTCAGC-3; and CST reverse, 5-GGTC-
CACTCAAACCACCAA-3. The probe sequence for CST mRNA was
5-FAM-TATGCTCGCTGTCTCGGCCG-TAMRA-3. The expression
levels of CST mRNA were determined relatively by means of a standard
curve generated in each experiment from cDNA isolated from a Raji cell
line and are given in arbitrary units.
SS receptor autoradiography
Binding of CST to sst in the human thymus was investigated by
autoradiography on unfixed cryosections using [125I-Tyr3]octreotide,
which was prepared as described previously (15). Thymic tissue was
collected at operation and immediately frozen, and small parts were
embedded in TissueTek (Miles Inc., Elkhart, IN) and processed for
cryosectioning. Sections (20 m) were mounted on gelatin-coated glass
slides and stored at 80 C for 3 d to improve adhesion of tissue to the
TABLE 1. Primers used for RT-PCR analysis
Primer Sequence (5—3) Expected size
HPRT (forward) -CAGGACTGAACGTCTTGCTC- 413 bp
HPRT (reverse) -CAAATCCAACAAAGTCTGGC-
SS (forward) -GATGCTGTCCTGCCGCCTCCAG- 349 bp
SS (reverse) -ACAGGATGTGAAAGTCTTCCA-
CST A (forward) -GCAAATTCGCTCTAAACACAGGA- 173 bp
CST A (reverse) -TTGGGAAGGAGGAGAGGAAAGAT-
CST B (forward) -CTCCAGTCAGCCCACAAGAT- 701 bp
CST B (reverse) -CAAGCGAGGAAAGTCAGGAG-
Primer sets for CST were derived and/or adapted from Ejeskar
et al. (9).
FIG. 1. Overview of the genomic organization of preprocortistatin.
Exons are boxed. Alternative splicing sites (indicated by p504 and
p2012) and primers used for expression studies are indicated. Se-
quences of different primer sets are listed in Table 1. Overview and
primers are adapted from Ejeskar et al. (9). CST-AF, Forward primer
for CST A mRNA; CST-AR, reverse primer for CST A mRNA; CST-BF,
forward primer for CST B mRNA; CST-BR, reverse primer for CST B
mRNA.
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slides. Autoradiography was performed as described previously (16) on
cryostat sections of human thymic tissue and cell pellets of stably sst2-
transfected CC531 colon adenocarcinoma cells, serving as a control for
binding of the different compounds to sst2 specifically. CC531 cells were
originally established from an adenocarcinoma and maintained by serial
passage after trypsinization in culture medium (17). The human sst2
cDNA in pBluescript was a kind gift from Dr. G. I. Bell (Howard Hughes
Medical Institute, Chicago, IL). This sst2 cDNA was excised from pBlue-
script and inserted into the Nhe-I and Sal-I cloning sites of the retroviral
vector pCI-neo (Promega Corp., Madison, WI). After exposure to Kodak
Biomax MS film (Eastman Kodak Co., Rochester, NY), the number of
pixels was quantified automatically using an AlphaImager 1220 analysis
imaging system (Alpha Innotech Corporation, San Leandro, CA). Values
are expressed as the percentage of specific binding on control sections
without unlabeled peptide.
Results
By RT-PCR studies, we investigated the expression of both
SS and CST mRNAs in various tissues and cells of the human
immune system. As shown in Fig. 2, panel 2, representing SS
mRNA expression, SS was only detected in whole thymic
tissue and TEC, not in thymocytes, pointing to an expression
of SS only in the epithelial compartment of the human thy-
mus and not in the lymphoid component, as demonstrated
previously (11). In addition, no SS mRNA was expressed in
human spleen and bone marrow. CST mRNA, however, was
clearly expressed in all tissues tested (Fig. 2, panels 3 and 4).
The expected 173-bp cDNA fragment of CST is detected in
all tissues in which the expected 701-bp cDNA fragment was
also found, because the set of primers encoding the short
fragment is in between the two primers encoding the longer
fragment (Fig. 1). When both cDNA fragments are detected,
no statement can be made about whether there might be
another isoform of the CST, because the shorter fragment
could be part of the longer fragment. However, compared
with human brain cDNA, the 701-bp fragment was expressed
relatively weakly in the tested samples. In human spleen, we
only detected the short, 173-bp cDNA fragment, whereas
both fragments were detected in the other three samples, i.e.
the thymus, thymocytes, and bone marrow. Next to the ex-
pression of SS mRNA in human TEC, expression of CST
mRNA was detected in these cells as well. As shown in Fig.
2, panel 2, SS mRNA was not detected in monocytes, mac-
rophages, dendritic cells, and PBMC, whereas in all of these
cells CST mRNA was clearly detectable. In monocytes, only
the short 173-bp fragment could be detected. The results of
RT-PCR for the long 701-bp fragment showed a very weak
signal, compared with human brain mRNA, and might even
be below the detection limit in some cell samples due to its
very weak expression. In addition, no SS mRNA expression
was detectable in macrophages activated with LPS during 24
and 48 h (data not shown). To further evaluate the expression
of SS and the potential two CST isoforms in lymphocytes, we
also performed RT-PCR analysis on B- and T-cells in periph-
eral blood of healthy volunteers and T- and B-cell lines with
different levels of maturation. The results of these studies are
summarized in Tables 2 and 3. In agreement with the ob-
servations in the primary human immune cell types, no
expression of SS mRNA could be detected. In B- and T-cells,
both fragments of CST were detected (Table 2). Surprisingly,
a clear difference was found in the expression of both forms
in B- and T-cell lines. Although the 173-bp cDNA CST frag-
ment was found in the majority of the T- (7 of 8) and B- (9
FIG. 2. Expression of SS and CST mR-
NAs in human immune tissues and cells.
Poly-A mRNA was prepared from hu-
man brain (HB), thymus (TH), thymic ep-
ithelial cells (TEC), thymocytes (TC),
bone marrow (BM), spleen (SP), mono-
cytes (MO), macrophages (MP), dendritic
cells (DC), and PBMCs (PB). cDNA was
synthesized and amplified using primers
specific for HPRT (413-bp fragment;
panel 1), SS (349-bp fragment; panel 2),
and two isoforms of CST (173 and 701 bp,
respectively; panels 3 and 4).
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of 10) cell lines, the longer fragment was detected in nearly
all T-cell lines (7 of 8), whereas only 2 of 10 B-cell lines
expressed this isoform (Table 3).
To evaluate differences in expression levels of CST mRNA
between the different human immune cells and tissues, Q-
PCR was performed. Results of the Q-PCR experiments are
summarized in Table 4.
As shown, significant differences in expression levels of
CST mRNA were observed between the different cells and
tissues. A relatively high level of CST mRNA was measured
in the human thymus and TEC, and a lower expression was
detected in spleen and human thymocytes, whereas in hu-
man bone marrow CST mRNA levels were below detection
limit for Q-PCR. In the cell samples, a relatively low expres-
sion level of CST mRNA was detected in PBMC and mono-
cytes, whereas expression of CST mRNA was considerably
higher in monocyte-derived macrophages and dendritic
cells, approximately 60- and 10-fold, respectively, compared
with monocytes. Regulation of CST mRNA expression was
studied in monocytes and monocyte-derived macrophages
cultured for 6 d. Results of these experiments are shown in
Fig. 3.
As described above, resting monocytes showed low ex-
pression of CST mRNA. When monocytes differentiated into
mature macrophages in vitro, CST mRNA levels increased
approximately 60-fold. LPS stimulation of both monocytes
and macrophages resulted in a 2- and 3-fold increase in CST
mRNA, respectively, compared with these cells in unstimu-
lated conditions.
To determine whether CST binds to human endogenously
expressed sst, we performed displacement studies using au-
toradiography on tissue sections of human thymus using
[125I-Tyr3]octreotide. [125I-Tyr3]octreotide binding was mainly
localized in the medullary region of the thymus. Unlabeled
octreotide, CST-17, and SS were used to investigate displace-
ment of [125I-Tyr 3]octreotide binding from its receptor, which
in the human thymus probably is sst2, as previously described
(11). Binding of [125I-Tyr3]octreotide was displaced in a dose-
dependent manner by unlabeled octreotide, SS, and CST-17.
Figure 4, left panel, shows that octreotide and SS both displaced
[125I-Tyr3]octreotide binding with high affinity (IC50 values of
6.8 1010 m and 1.9 109 m, respectively). CST-17 displaced
[125I-Tyr3]octreotide binding as well, however, with a slightly
lower affinity (IC50 value of 2.2  10
8 m), compared with SS
and octreotide. Binding and displacement of [125I-
Tyr3]octreotide to sst2 receptors was confirmed on human sst2-
transfected cells as shown in Fig. 4 (right panel). The IC50 values
for displacement of [125I-Tyr3]octreotide binding to sst2 recep-
tors were 1.2 109, 1.7 109, and 4.0 109 m, respectively,
for SS, octreotide, and CST-17.
Discussion
Neuropeptide hormones are involved in a pattern of the
complex interactions that exist between the human neuroen-
docrine and immune system. A place in this network might
be hypothesized for SS and its receptors as well. The sst have
been demonstrated in various endocrine and lymphoid tis-
sues by classical ligand binding studies (20–22). SS mRNA
itself has been detected only in the epithelial component of
TABLE 2. mRNA expression of SS and CST in different
peripheral blood cells
Cell type HPRT SS CST A CST B
PBMC    
Monocytes    
B-lymphocytes    
T-lymphocytes    
Data represent mRNA expression of HPRT, SS, the 173-bp frag-
ment of CST (CST A), and the 701-bp fragment of CST (CST B) in
different cell subsets of the human peripheral blood.
TABLE 3. mRNA expression in different T- and B-cell lines
Cell line HPRT sst2 SS CST A CST B
T-cell lines
HSB-2  b   
Molt-3     
ALL-1     
MT-1  b   
Peer  a   
Molt-16     
HuT-78     
HPB-ALL  a   
B-cell lines
RS4,11     
Nalm-1     
BV-173     
Nalm-6     
Raji     
Daudi     
JY  b   
TMM  b   
LP-1     
L-363     
Total mRNA was isolated from CD3- (HSB-2, Molt-3, ALL-1, MT-
1), TCR- (Peer), or TCR- (Molt-16, HuT-78, HPB-ALL) T-cell
lines and precursor (RS4,11, Nalm-1, BV-173, Nalm-6), mature (JY,
TMM), Burkitt (Raji, Daudi), and plasma (LP-1, L-363) B-cell lines.
On these samples RT-PCR analysis was performed as described in
Materials and Methods. Specific primer sets for SS and CST [173-bp
(CST A) and 701-bp fragment (CST B)] were used to detect SS or CST
mRNA.
a Data of sst2 expression are derived from Lichtenauer et al. (18).
b Data of sst2 expression are derived from van Hagen et al. (19).
TABLE 4. CST mRNA expression levels in different human
immune cells and tissues
Sample n Relative amount ofCST mRNA
% Relative
to TEC
Thymus 3 22  12 71
TEC 3 31  8 100
Thymocytes 2 4.6  0.5 15
Spleen 2 2.8  0.9 9
Bone marrow 2  Detection limit
PBMC 3 0.8  0.2 2.5
Monocytes 4 0.15  0.05 0.5
Macrophages 4 9.6  1.4 31
Dendritic cells 4 1.7  0.3 5.5
Data represent the quantified expression levels of CST mRNA in
different human immune cells and tissues. Values are presented as
arbitrary units, relative to a standard curve generated from a Raji cell
line and are results from Q-PCR experiments using 50 ng/l total
RNA for the reverse transcription reaction per sample. n represents
the number of samples investigated, and the relative amount of CST
mRNA is expressed as the mean  SD of these samples. In the last
column, expression of CST mRNA is shown as a percentage relative
to expression of CST mRNA in human TEC, which is set at 100%.
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the thymus (11), although not in thymocytes. In addition, it
is not known whether the peptide is expressed in other
organs of the human hematological and immune systems,
like spleen and bone marrow. The presence of sst, however,
in these tissues suggests a regulatory role of these receptors
in the human immune system. In contrast to the human
immune system, evidence has been provided for the expres-
sion and functional role of SS in rat (23) and murine (24)
lymphoid tissues. In mice, SS mRNA itself has been detected
in splenic macrophages but not in splenic lymphocytes (25),
whereas rat B- and T-lymphocytes of spleen and thymus
synthesize and release SS (26). In the human immune system,
however, it is yet unknown whether SS plays a regulatory
role and whether this is comparable to the situation in ro-
dents. Moreover, striking differences between human and
rodent species have been demonstrated with respect to the
expression of sst subtypes in immune cells. In murine im-
mune cells, predominantly sst2 and sst4 are expressed,
whereas in human immune cells, predominantly sst2 is ex-
pressed and to a lesser extent sst3 (18). In a previous study,
we found that SS mRNA was only expressed in the human
thymus and TEC, but not in the thymocyte compartment of
the thymus (11). Our present study shows that none of the
other investigated tissues, nor lymphoid cell samples, ex-
pressed SS mRNA. Therefore, we analyzed whether a po-
tential novel endogenous ligand for the sst in the human
immune system, other than SS itself (i.e. CST), is expressed.
CST is known to have high binding affinity to all different
human sst subtypes (8), due to its structural resemblance
to SS.
We found the expression of both SS mRNA and CST
mRNA in human thymus and also in isolated TEC, whereas
squeezed thymocytes expressed CST mRNA only (11). In
human spleen and bone marrow, no SS mRNA, but only CST
mRNA was detected. Moreover, in the different single cell
types tested, i.e. human PBMC, T- and B-lymphocytes, mono-
cytes and their functionally derived cells, i.e. macrophages
and dendritic cells, no SS mRNA was detected, whereas CST
mRNA was clearly expressed in all of these cells. These data
point to a rather universal expression of CST in immune cells.
By Q-PCR, significant differences in CST mRNA expression
levels were detected between the human immune cells and
tissues. High expression of CST mRNA was detected in thy-
mic tissue and TEC, although we found lower expression in
FIG. 3. Regulation of CST mRNA expression in monocytes and mac-
rophages. The bars represent expression of CST mRNA in monocytes
and macrophages without () or with () LPS stimulation. The bars
represent means SD of four independent experiments and represent
arbitrary units relative to a standard curve generated from a Raji cell
line as results of Q-PCR using 50 ng/l total RNA in the reverse
transcription reaction per sample. Monocytes, 0.15 0.05; monocytes
 LPS, 0.3 0.04; macrophages, 9.6 1.4; and macrophages LPS,
28.9 3.2. *, P 0.0001 vs. monocytes; #, P 0.002; and, P 0.0001
vs. cells without LPS.
FIG. 4. Displacement of [125I-Tyr3]octreotide binding on cryostat sections of human thymic tissue (left) and cell pellets of human sst2-expressing
cells (right). Twenty- and 10-m sections, respectively, were incubated with [125I-Tyr3]octreotide without or with increasing concentrations of
unlabeled SS, octreotide, or human CST-17. After exposure to Kodak Biomax MS film, the number of pixels was quantified automatically using
an AlphaImager 1220 analysis imaging system (Alpha Innotech Corporation, San Leandro, CA). Values are expressed as the percentage of
specific binding on control sections without unlabeled peptide. Symbols represent displacement by SS (), octreotide (f), or CST-17 ().
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thymocytes and splenic tissue, and in bone marrow expres-
sion levels were even below detection limit for Q-PCR. The
meaning of these differences in expression levels is still un-
known, but it might be hypothesized that, although CST
mRNA is rather universally expressed in immune cells and
tissues, CST plays a more important regulatory role in certain
tissues, i.e. the tissues in which CST mRNA is highly ex-
pressed. Moreover, we evaluated SS mRNA expression lev-
els in TEC (data not shown) and found very low expression
levels of SS, whereas high levels of CST mRNA were de-
tected. This difference might indicate that CST plays a more
important role in this cell system than SS. However, this
hypothesis should be further studied. Interestingly, differ-
ences in CST mRNA expression levels were observed be-
tween monocytes and their functionally derived cells, i.e.
macrophages and dendritic cells. Although expression of
CST mRNA was relatively low in monocytes, expression in
macrophages and dendritic cells was considerably higher
(approximately 60- and 10-fold, respectively), pointing to an
up-regulatory mechanism for CST mRNA expression during
differentiation and maturation of monocytes into both mac-
rophages and dendritic cells and, possibly, a more important
role for CST in the mature immune system. In concordance
with this hypothesis, we observed in our LPS-stimulation
experiments that stimulated monocytes and macrophages
expressed approximately 3-fold higher levels of CST mRNA
than unstimulated cells did. From these experiments, we
hypothesize that CST may have a regulatory role in the
human immune system in inflammatory reactions possibly
acting via the sst, rather than SS, which is not expressed itself
in cells and tissues of the human immune system. However,
the exact significance of CST in the human immune system
needs to be established.
In the present study, we detected two differently sized
fragments of CST mRNA, one 173-bp and one 701-bp frag-
ment (Fig. 1). Because one of these fragments (the 701 bp) was
very weakly expressed, compared with its expression in the
human brain, this might explain why in a previous study this
form was not detectable in leukocytes (9). Although in our
study the majority of primary human immune cells and
tissues express both isoforms, we observed a clear difference
in their expression in human T- and B-cell lines. In contrast
to the T-cell lines, B-cell lines expressed mainly one isoform.
No clear relationship between the absence and the presence
of the expression of the 701-bp fragment and the level of
maturation was observed. The exact biological significance of
the detection of the two isoforms is still unknown but sug-
gests a differential regulatory mechanism. According to the
literature (9), both sets of primers should detect the sequence
coding region for the bioactive form of CST, i.e. CST-17.
Although expression of CST mRNA is abundant in cells and
tissues of the human immune system and differences in
expression levels have been demonstrated, the question still
stands whether the CST mRNA is successfully translated into
the CST protein in these cells and tissues. Further studies will
be necessary to clarify this issue. However, our observations
that CST mRNA expression was up-regulated during dif-
ferentiation and maturation of monocytes into macrophages
and dendritic cells and by LPS stimulation of monocytes and
macrophages suggest that CST itself plays at least a role in
these cells.
To investigate whether CST was able to bind to sst in
human thymus, sst autoradiography was performed. We
found that CST concentration dependently was able to dis-
place [125I-Tyr3]octreotide binding in the human thymus. It
is known that [125I-Tyr3]octreotide binds to sst2 receptors
in the human thymus. These receptors are predominantly
localized in the medullary region of this organ (22, 27). Com-
pared with SS and octreotide, CST has a slightly lower
affinity for sst2 in human thymic tissue (approximately
20-fold). These data demonstrate for the first time that
CST is able to displace with a relatively high affinity
[125I-Tyr3]octreotide binding from sst endogenously ex-
pressed in a human sst-expressing organ. As indicated be-
fore, previous studies have already shown that CST has a
high affinity for the different human sst subtypes in stably
transfected cell lines (8). In agreement with these observa-
tions, we also found that CST-17 displaced [125I-Tyr 3]oct-
reotide binding from sst2 receptors in a transfected cell model
with an affinity comparable with that of SS and octreotide.
Because no SS mRNA, but only CST mRNA was detected in
the samples tested, we hypothesize on the basis of both the
expression of CST and the observation that CST is able to
bind to human sst2 receptors, that CST, rather than SS, may
act via the sst in the human immune system in an autocrine
and/or paracrine function. With regard to the slightly lower
binding affinity of CST to sst, the question can be addressed
whether a specific CST receptor, for which CST has a higher
binding affinity, is present in lymphoid cells and tissues. In
brain, evidence for a specific CST receptor has been proposed
on the basis of findings that the effects of CST in human brain
can be distinct from those found for SS (28). However, studies
in rat and mouse brain showed that CST and SS expression
is differently regulated by different stimuli (29) and SS and
CST both use different signal transduction pathways to gen-
erate their effects (29). These findings might explain the dif-
ferent effects of SS and CST in the brain as well, when both
peptides would act via the sst.
Functional aspects of CST in the human immune system
are unknown at present. There is, however, a striking re-
semblance between CST/SS and the family of chemokines.
The latter are chemotactic cytokines that coordinate devel-
opment, differentiation, trafficking, and effector functions of
leukocytes and their progenitors (30). As CST and SS, che-
mokines are also cyclic peptides that are characterized by
their relative position of the cysteine residues. They all in-
duce cell migration and activation by binding to specific G
protein-coupled seven transmembrane receptors on the tar-
get cells (30). SS analogs have a predominantly immunosup-
pressive effect in the human immune system but exert pow-
erful, unique migration-inducing effects on normal and
leukemic hematopoietic progenitors (31).
In summary, we described for the first time that no SS
mRNA was detectable in different human immune and he-
matological cell types, whereas in all samples tested CST
mRNA was found. Significant differences in expression lev-
els were observed between the different immune cells and
tissues investigated. CST mRNA was up-regulated during
differentiation of monocytes into both macrophages and
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dendritic cells and by LPS stimulation of monocytes and
macrophages, pointing to a regulatory role of CST in the
human immune system. Interestingly, human B-cell lines
mainly expressed only one of two cDNA fragments, pointing
to the existence of two CST isoforms in the human immune
system. Considering the important role of dendritic cells and
macrophages in autoimmune diseases and the expression of
sst2 receptors on these cell types (16, 32), the functional sig-
nificance of CST in these cells should be evaluated in further
studies. In addition, human T- and B-lymphocytes may ex-
press sst, pointing to a potential role of CST in the function
of these cells as well.
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